General Information

Mice: C57BL/6

The human LRRK2 protein is expressed under the control of a mini version of the neuronal specific promoter Thy1.2.

Endogenous LRRK2: yes

Corresponding human genotype: LRRK2 is a major known genetic contributor to Parkinson’s disease.

 Targeted gene: LRRK2

References: Garcia-Miralles 2015

Transgene expression

  • 4 and 11 months: The total level of LRRK2 protein is 2 times higher than the level measured in the brain of non-transgenic animals. Expression is found at high level in the cortex and hippocampus but no expression of the human LRRK2 protein is detected in the SN.

Neurodegeneration

  • 12-13 months: No obvious neurodegeneration is observed in the SN.

Dopamine Homeostasis

  • Not reported

Inclusions

  • 11 months: No differences in the levels of alpha-synuclein are observed in the brain of transgenic animals.

Motor Behaviours

  • Not reported

Response to dopaminergic treatment

  • Not reported

Non-motor Behaviours

  • Not reported

Electrophysiology

  • Not reported

Neuroinflammation

  • Not reported